ライフサイエンスコーパス: babesiosis

1 f an immunosuppressed patient with relapsing babesiosis.

2 Lyme disease, 26 (11%) were coinfected with babesiosis.

3 rochetes and the piroplasm that causes human babesiosis.

4 ed in the United States to screen for bovine babesiosis.

5 e in the routine clinical diagnosis of acute babesiosis.

6 ad had a splenectomy and had a fatal case of babesiosis.

7 e combination therapy for treatment of human babesiosis.

8 months after the diagnosis and treatment of babesiosis.

9 pecimens are used to diagnose active HGA and babesiosis.

10 n plus quinine is often used to treat severe babesiosis.

11 small mammals, is the primary cause of human babesiosis.

12 asitemia and parasite clearance during acute babesiosis.

13 omycin plus atovaquone is effective for mild babesiosis.

14 nt, and prevention of Lyme disease, HGA, and babesiosis.

15 rease in the risk of transfusion-transmitted babesiosis.

16 ephalitis, borreliosis, tick-borne fever and babesiosis.

17 demiology, treatment and prevention of human babesiosis.

18 e basis of effective vaccines against canine babesiosis.

19 lasmosis, cryptosporidiosis, coccidiosis and babesiosis.

20 inical suspicion for transfusion-transmitted babesiosis.

21 ses are involved in protection against acute babesiosis.

22 of the host may influence protection against babesiosis.

23 and adaptive immunity in resistance to acute babesiosis.

24 nts experienced symptoms suggestive of acute babesiosis.

25 producible for use in the diagnosis of acute babesiosis.

26 For the treatment of babesiosis, a regimen of atovaquone and azithromycin is

27 Background Babesiosis, a tickborne zoonotic disease caused by intra

28 Babesiosis, a zoonosis caused by the protozoan Babesia m

29 Transplant patients may contract babesiosis after tick exposure and/or via blood transfus

30 ity of the PCR-based test with patients with babesiosis and a group of asymptomatic subjects residing

31 We report a severe case of babesiosis and hemophagocytic syndrome in an asplenic re

32 activation and erythrocyte cytoadherence in babesiosis and malaria have exploited these similarities

33 ities and differences in the pathogenesis of babesiosis and malaria should lead to additional fundame

34 me disease, human granulocytic anaplasmosis, babesiosis and other diseases.

35 Most clinical cases and fatalities of babesiosis are caused by Babesia microti Current treatme

36 , human granulocytic anaplasmosis (HGA), and babesiosis are emerging tick-borne infections.

37 in patients with concurrent Lyme disease and babesiosis are greater than in patients with either infe

38 tive measures for preventing transmission of babesiosis by blood transfusion are needed.

39 The risk of acquiring babesiosis by blood transfusion is largely unknown since

40 as isolated from a Connecticut resident with babesiosis by hamster inoculation and adapted to C3H/HeJ

41 patients 2 to 4 weeks after the diagnosis of babesiosis, by which time all the patients had had clini

42 Human babesiosis caused by Babesia microti is an emerging tick

43 Babesia microti Current treatment for human babesiosis consists of two drug combinations, atovaquone

44 total of 86 patients received a diagnosis of babesiosis during the 7.5-year study period; 18 of these

45 the United States can have life-threatening babesiosis even though they are seronegative to B. micro

46 Babesiosis followed its normal course of infection in co

47 Diagnosis and successful therapy of babesiosis following transfusion.

48 Babesiosis (formerly known as piroplasmosis) is a tick-b

49 te babesiosis, we tested patients with acute babesiosis from a site in New England where the disease

50 Babesiosis has long been recognized as an economically i

51 ne hemolytic anemia [WAHA]) in patients with babesiosis has not previously been well described.

52 Canine babesiosis has recently been recognized as an emerging i

53 e the poor ecological fitness of B. microti, babesiosis has recently emerged in areas endemic for Lym

54 siosis, particularly transfusion-transmitted babesiosis, has been emerging as a major threat to publi

55 In areas where both Lyme disease and babesiosis have been reported, the possibility of concom

56 serve as vectors of pathogens causing human babesiosis, human granulocytic anaplasmosis, and tick-bo

57 may result in the appearance of transfusion babesiosis in areas less familiar with these parasites.

58 ctivity with Babesia divergens, which causes babesiosis in cattle and humans in Europe, but that it h

59 Babesia bovis, the causative agent of severe babesiosis in cattle, was previously shown to undergo an

60 Babesia canis is the agent of the canine babesiosis in Europe.

61 de evidence for radical cure of experimental babesiosis in immunodeficient mice using a combination o

62 etts, is the same organism that caused human babesiosis in Missouri and Kentucky, on the basis of mor

63 ck-borne red blood cell parasite that causes babesiosis in people.

64 transmit both strains, resulting in virulent babesiosis in recipients.

65 The duration of antimicrobial therapy for babesiosis in severely immunocompromised patients should

66 in southern New England are coinfected with babesiosis in sites where both diseases are zoonotic.

67 Physicians should consider babesiosis in the differential diagnosis of a febrile he

68 the impact of simultaneous Lyme disease and babesiosis in the mouse model.

69 The primary etiological agent of babesiosis in the United States is B. microti.

70 Human babesiosis in the United States is caused predominantly

71 eased recognition of the prevalence of human babesiosis in the United States, together with rising co

72 iroplasms previously known to cause zoonotic babesiosis in the United States.

73 majority of cases of transfusion-transmitted babesiosis in the United States.

74 e, is the primary etiological agent of human babesiosis in the United States.

75 We sought evidence of babesiosis in three residents of New Jersey who were sus

76 tory responses to antimicrobial treatment of babesiosis, including clearance of Babesia microti paras

77 ultiple red blood cell transfusions acquired babesiosis infection with Babesia divergens-like/MO-1 or

78 Babesiosis is a malaria-like illness transmitted by the

79 Babesiosis is a potentially life-threatening disease cau

80 Human babesiosis is a tick-borne multisystem disease caused by

81 Babesiosis is a tick-borne zoonosis caused by protozoans

82 Babesiosis is a tick-borne, malaria-like illness known t

83 PURPOSE OF REVIEW: Babesiosis is a zoonosis, a disease communicable from an

84 Human babesiosis is an emerging zoonosis that is transmitted b

85 Babesiosis is an emerging zoonosis with important public

86 ng in a region in southern New England where babesiosis is enzootic.

87 The risk of transfusion-transmitted babesiosis is higher than usually appreciated and in end

88 In endemic areas transfusion-transmitted babesiosis is more prevalent than usually believed.

89 Prompt diagnosis is important since babesiosis is responsive to antibiotic therapy and, untr

90 icroti, the primary causative agent of human babesiosis, is a major public health concern in the Unit

91 The diagnosis of babesiosis may be confused with malaria and should be in

92 ossible cases of Lyme borreliosis (n = 142), babesiosis (n = 41), and HME (n = 21).

93 ens in 58 subjects with non-life-threatening babesiosis on Nantucket, on Block Island, and in souther

94 derstudied zoonotic genus Babesia In humans, babesiosis, particularly transfusion-transmitted babesio

95 S rRNA gene of Babesia microti, the dominant babesiosis pathogen in the United States.

96 gene sequences of parasite isolates from six babesiosis patients from Nantucket.

97 id not receive specific therapy, symptoms of babesiosis persisted for a mean of 114 days in five subj

98 Babesiosis, recognized since biblical times as an import

99 Most cases of babesiosis reported in the United States have been tickb

100 Our results indicate that resolution of babesiosis requires CD4 T cells and a novel mechanism of

101 Babesiosis should be included in the differential diagno

102 Babesiosis treatment failures with standard therapy have

103 ick transmission showed no clinical signs of babesiosis, unlike those receiving intravenous challenge

104 relationship, we developed a mouse model of babesiosis using a novel clinical isolate of B. microti.

105 Babesiosis, usually caused by the intraerythrocytic para

106 Conclusions We documented post-babesiosis WAHA in patients who did not have a history o

107 One patient diagnosed with babesiosis was also seropositive for ehrlichiosis.

108 us diseases (Lyme disease, ehrlichiosis, and babesiosis) was conducted among 230 residents of a semir

109 from Babesia divergens, the agent of bovine babesiosis, was able to induce complete protection again

110 ing data on cases of transfusion-transmitted babesiosis, we compared the proportions of screened vers

111 hat occurred after treatment of patients for babesiosis, we conducted a retrospective cohort study of

112 cent-antibody procedure for diagnosing acute babesiosis, we tested patients with acute babesiosis fro

113 no reported cases of transfusion-transmitted babesiosis were associated with screened donations (i.e.

114 Overall, 29 cases of transfusion-transmitted babesiosis were linked to blood from infected donors, in

115 is, which is caused by Borrelia burgdorferi, babesiosis, which is caused by Babesia microti, and huma

116 The specific diagnosis of babesiosis, which is caused by the piroplasm Babesia mic

117 ective cohort study of all the patients with babesiosis who were cared for at our center from January

118 interleukin-12 (IL-12) in the model of acute babesiosis with the WA1 Babesia.

119 s for highly immunocompromised patients with babesiosis, with no parasites detected on blood smear fo

120 If reintroduced into the United States, babesiosis would cause significant mortality in the naiv